Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Initiates Coverage On Avidity Biosciences with Strong Buy Rating, Announces Price Target of $29

Raymond James analyst Steven Seedhouse initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Strong Buy rating and announces Price Target of $29.
byBenzinga Newsdesk
July 12, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Raymond James analyst Steven Seedhouse initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Strong Buy rating and announces Price Target of $29.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts